glp-1 shortage guidance How GLP-1s Broke Healthcare Distribution Prioritizing Health | Diabetes, Diet

Real-world evidence suggests favorable cardiovascular effects, with some retrospective analyses showing tirzepatide may reduce major cardiovascular events by approximately 14% compared to semaglutide

According to FDA prescribing information, the most frequently reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain

Severe, worsening, or functionally impairing fatigue warrants prompt clinical review

GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans

Uncommon but warrants a call: Severe, persistent abdominal pain radiating to the back

Both drugs employ tirzepatide to engage with the body's GIP and GLP-1 receptors, aiding insulin secretion and appetite suppression